

BSRBR-RA Study Newsletter

June 2021

Rheumatoid Arthritis Register

As we move through 2021, we appreciate • that the NHS remains under extreme pressure and are thankful for the new registrations and follow up data that you have provided for BSRBR-RA participants throughout this difficult period. The study remains open to new registrations and submissions of follow-up information.

As an observational study, the data we receive are obtained from clinical case notes so we are appreciative of any data that you are able to provide at any time that is possible to do so, however many months down the line this may be.

- The BSRBR-RA study team continue to work from home and are contactable via email.
 - Participants can only be registered and followed up via the online unfortunately database paper registration forms cannot be accepted due to remote working. Training and tutorials for the database are here: https://www.bsrbr.org/database/train ing-help/
 - **NHS** successfully **75** Trusts are submitting data using the online system – thank you for your support!

Recent Publications using BSRBR-RA data

• Bechman et al.

"Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the **British Society for Rheumatology Biologics** Register".



"Cervical screening uptake and rates of cervical dysplasia in the British Society for **Rheumatology Biologics** Register for Rheumatoid Arthritis".



Hamann et al.



"Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA".

COVID-19 Update

Please include reports of any suspected or confirmed COVID-19 cases for BSRBR-RA participants in the adverse events section of the next scheduled follow up. A Serious Infection 'Event of Special Interest' form should be completed for all serious events of COVID-19.

In the coming weeks you will see changes to the data collection forms at baseline and follow-up to collect detail around COVID-19 vaccinations (name of vaccine, date of first dose and second dose) as well as details of COVID-19 cases prior to baseline registration.

• Email: biologics.register@manchester.ac.uk

Twitter: @BSRBR RA


Remote Consent

There may be times when you identify eligible participants to approach for BSRBR-RA, but who may not be seen in clinic during the 6 month window for recruitment after the new therapy has started. In these cases, it may be appropriate to use a 'remote' method

of consenting participants. These differ slightly for patients who are new to the study and for those who are current patients but are being reregistered in a new cohort - outlined below.

If you need any postage stamps for remote consent please get in touch - we have a supply of these that can be posted out.





Step 1 and Step 2 can be done in any order.

Person taking consent phones the potential participant to explain the study and answer any

questions

(y)

Step Three

Study participant signs the consent form and posts it back to the hospital, along with the HAQ and EQSD







If you don't have a DAS-28 for when the participant started therapy, please use the closest prebiologic score from the patient notes.





consent form.

Study participant can be

registered in the online portal.

Please remember to upload the








Sten Four

Person taking consent countersigns the consent form, posts a copy back to the participant and puts original form in the patient notes.

Remote consent for re-registration of existing BSRBR-RA participants



Step One

If the participant has any questions about re-consenting, they can contact the research team on the details provided within the letter.





Study participant signs the re-consent form and posts it back to the hospital, along with the HAQ and EQ5D.

Step Two







If you don't have a DAS-28 for when the participant started therapy, please use the closest prebiologic score from the patient notes.



Study participant can be reregistered in the online database after a <u>switch request</u> has been made in the original Study ID. Please remember to upload the re-consent form.



Step Four





Step Three

Person taking consent countersigns the re-consent form, posts a copy back to the participant and puts original form in the patient